Neovascular Glaucoma
Community Case in nAMD
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Retinal Disease Digest on nAMD: Opportunities for Optometrists
This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc., and Ocular Therapeutix, Inc.
Clinical Trial Updates in nAMD, DME, RVO, MacTel, and GA Management
This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc.; Genentech, a member of the Roche Group; Neurotech Pharmaceuticals, Inc.; Astellas; EyePoint Pharmaceuticals, Inc.; Opthea Ltd.; Topcon Healthcare, Inc.; Outlook Therapeutics; REGENXBIO Inc.; Ocuphire Pharma; and Carl Zeiss Meditec, Inc.
Taming the Tide: Management of Persistent Retinal Fluid in nAMD and DME
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
nAMD and DME Management: Game-Changing Sustained Delivery Platforms
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Clinical Consultations™: Novel Therapeutic Targets in Neovascular Retinal Diseases – A Focus on the Roles of VEGF-C & D
This activity is supported by an educational grant from Opthea.
Researchers identify factors associated with severe vision loss in neovascular glaucoma
The progression of vision loss among patients with neovascular glaucoma appeared linked to factors such as the disease stage at diagnosis, age, sex, a history of type 2 diabetes and insurance status, according to study results.
Personalized Approaches for Treating nAMD and DME
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Rapid Response From Angiogenesis 2024: State of the Science in Management of nAMD, DME, and RVO
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Socioeconomic factors play role in neovascular glaucoma outcomes
NEW YORK — Patients from an urban population who presented with advanced neovascular glaucoma had poor outcomes, according to a study.